Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
- 2025-04
-
In conclusion there are only a few experimental reports eval
2025-04-03
In conclusion, there are only a few experimental reports evaluating the influence of Sulfo-NHS-Biotin on allergy. With the exception of studies using macrolides, most point to their harmful effect on the severity of this disease. Future studies will be crucial to define the impact of antibiotic use
-
br Other Strategies for HIF Inhibition NSC is another HIF
2025-04-03
Other Strategies for HIF-α Inhibition NSC-644221 is another HIF-α inhibitor acting at the translational level, independently of proteasomal degradation and VHL status, and is devoid of DNA damage-inducing properties [70]. NSC-644221 arrests InstaBlue Protein Stain Solution in G2–M through a cell
-
Under some pathological conditions AT
2025-04-01
Under some pathological conditions, AT1R internalization is decreased when agonist exposure is prolonged. This weakens or removes the AT1R desensitization effect and leads to AT1R and downstream signal overactivation. AT1R overactivation can result in continued biological effects such as sustained v
-
Introduction The burden of cardiovascular disease CVD is und
2025-03-29
Introduction The burden of cardiovascular disease (CVD) is undisputed, accounting for approximately a third of global deaths (17.5 million people in 2012) (WHO, 2012). Atherosclerosis leads to the development of coronary heart disease (CHD) which accounts for more than 40% of these deaths (WHO, 201
-
The chronic induction of skeletal muscle
2025-03-28
The chronic induction of skeletal muscle AMPK activity is an attractive therapeutic approach for DMD, as it addresses multiple cellular pathways needed for powerful phenotypic plasticity, including activation of the slow oxidative myofiber program, corrective autophagic signaling, as well as regulat
-
br Results The newly synthesized leucine ureido derivatives
2025-03-27
Results The newly synthesized leucine ureido derivatives were firstly evaluated for their enzymatic inhibition using porcine kidney APN (Microsomal, Biocol) with bestatin as the positive control (Table 1). One isoleucine ureido derivative 14 and phenylglycine ureido derivative 15 were also synthe
-
HotStart™ 2X Green qPCR Master Mix Kuda et al reported that
2025-03-26
Kuda et al. (1997) reported that the activity of aminopeptidase A (ApA) but not aminopeptidase B (ApB) nor aminopeptidase N (ApN) was decreased in plasma from patients with Alzheimer's disease (AD). More recently Puertas et al. (2013) reported that the activities of plasma ApA, ApB, ApN and IRAP wer
-
Introduction Rapeseed oil production is
2025-03-26
Introduction Rapeseed oil production is very important not only because of its application in food industry, but also in petrochemical branch. Additionally, post-extraction meal and bagasse from oilseed rape are important sources of proteins in animal feedstuffs production. Oilseed rape (Brassica n
-
In summary our data have shown that one mechanism by
2025-03-25
In summary, our data have shown that one mechanism by which glucose may mediate monocyte–endothelial cell interaction in the retinal endothelial cells is via the 12/15-LO pathway Furthermore, our current and previously published data [20,22] indicate a differential role of endothelial 12/15-LO versu
-
MD was the recipient of the Intergroupe Francophone de Canc
2025-03-03
MD was the recipient of the Intergroupe Francophone de Cancérologie Thoracique (IFCT) Alain Depierre Grant in 2014. JP was the recipient of the ARISTOT (Association de Recherche, d’Information Scientifique et Thérapeutique en Oncologie Thoracique) grant in 2016. Conflicts of interest statement
-
Synthesis of the pterin carboxamides was achieved as shown
2025-03-03
Synthesis of the pterin-7-carboxamides was achieved, as shown in , based on a previously reported method that utilizes DBU as a key additive to dissolve pterin in organic solvents and accelerate the reaction., With this method, the pterin-amino Ion channel screening library conjugates (–) were rea
-
br Introduction Diabetes mellitus DM is a chronic metabolic
2025-03-03
Introduction Diabetes mellitus (DM) is a chronic metabolic disorder characterized by elevated levels of glucose in the blood. Type 1 diabetes is characterized by insufficient insulin production and needs a daily administration of insulin. Actually, no prevention is known for Type 1 diabetes. Type
-
br A novel therapeutic strategy based on
2025-03-03
A novel therapeutic strategy based on the APN and obesity paradoxes As shown above, the relationship of the serum APN concentration with health and disease states shows an inverted-U correlation, suggesting that moderate concentrations of serum APN are beneficial (Fig. 3). Given that both hypo- a
-
br Co http www apexbt com media diy images
2025-03-03
Conclusions This paper is the first meta-analysis about the association between SRD5A2 V89L polymorphism and hypospadias risk. The results of this meta-analysis have revealed that V89L polymorphism definitely increases the risk of hypospadias, and the C allele is a genetic risk factor for hypospa
-
Small kinase inhibitors have been developed to block AXL by
2025-03-03
Small kinase inhibitors have been developed to block AXL by interacting with the kinase cytoplasmic ATP binding site. Up to date, no AXL selective kinase inhibitors are marketed. As depicted in , some marketed kinase inhibitors such as Bosutinib and Cabozantinib or kinase inhibitors in clinical pha